Can more radiation save rectums? new trial aims to find out

NCT ID NCT04095299

Recruiting now Disease control Sponsor: Vejle Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial compares standard versus higher-dose radiotherapy, combined with chemotherapy, in 162 people with early low or mid rectal cancer. The goal is to see if a higher dose helps more patients achieve a complete response and avoid surgery, preserving their rectum. Participants will be monitored closely for two years to check if the cancer stays away.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiotherapy (standard or high dose) plus chemotherapy (capecitabine)
What this could lead to: If successful, this could offer a way for some early rectal cancer patients to avoid surgery and keep their rectum, improving quality of life.
What could go wrong: This is a phase 3 trial, but it's still uncertain if the higher dose will work better. Risks include side effects from radiation and chemotherapy, and the cancer may still come back.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF RECTUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF RECTUM

Contacts and locations

Locations

Aalborg University Hospital
RECRUITING

Aalborg, Denmark
Copenhagen University Hospital, Righshospitalet and Bispebjerg Hospital
RECRUITING

Copenhagen, Denmark
Department of Oncology, Vejle Hospital
RECRUITING

Vejle, Denmark
Zealand University Hospital, Næstved
RECRUITING

Næstved, Denmark
Zealand University Hospital, Roskilde
RECRUITING

Roskilde, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.